posted on 2016-08-05, 00:00authored byErik C. Hett, Robert E. Kyne, Ariamala Gopalsamy, Michael
A. Tones, Hua Xu, Guene L. Thio, Edward Nolan, Lyn H. Jones
Small molecule selectivity is an
essential component of candidate
drug selection and target validation. New technologies are required
to better understand off-target effects, with particular emphasis
needed on broad protein profiling. Here, we describe the use of a
tritiated chemical probe and a 9000 human protein microarray to discern
the binding selectivity of an inhibitor of the mRNA decapping scavenger
enzyme DcpS. An immobilized m7GTP resin was also used to
assess the selectivity of a DcpS inhibitor against mRNA cap-associated
proteins in whole cell extracts. These studies confirm the exquisite
selectivity of diaminoquinazoline DcpS inhibitors, and highlight the
utility of relatively simple protein microarray and affinity enrichment
technologies in drug discovery and chemical biology.